Search research articles
Contact Us
Filters
Showing results (251-260 of 266) with videos related to
Page
of 27
Sort By:
European Urology
|
March 24, 2023
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
Cell
|
February 1, 2024
SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion
Giuseppe Leuzzi, Alessandro Vasciaveo, Angelo Taglialatela, et al.
Immunity
|
August 7, 2024
The cytokine Meteorin-like inhibits anti-tumor CD8<sup>+</sup> T cell responses by disrupting mitochondrial function
Christopher M Jackson, Ayush Pant, Wikum Dinalankara, et al.
The New England Journal of Medicine
|
June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
BMC Systems Biology
|
November 7, 2015
A multi-omic analysis of human naïve CD4+ T cells
Christopher J Mitchell, Derese Getnet, Min-Sik Kim, et al.
Journal for Immunotherapy of Cancer
|
April 18, 2020
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
Paolo Antonio Ascierto, Bernard A Fox, Walter J Urba, et al.
Cancer Discovery
|
December 9, 2024
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Lisa N Chesner, Fanny Polesso, Julie N Graff, et al.
Nature Medicine
|
August 15, 2022
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Christine D Palmer, Amy R Rappaport, Matthew J Davis, et al.
The Lancet. Oncology
|
June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
Mohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
European Urology
|
January 30, 2023
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study
Noah M Hahn, Michael A O'Donnell, Jason A Efstathiou, et al.
Page
of 27
Search research articles
Search
Showing results (251-260 of 266) with videos related to
Sort By:
Page
of 27
European Urology
|
March 24, 2023
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
Cell
|
February 1, 2024
SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion
Giuseppe Leuzzi, Alessandro Vasciaveo, Angelo Taglialatela, et al.
Immunity
|
August 7, 2024
The cytokine Meteorin-like inhibits anti-tumor CD8<sup>+</sup> T cell responses by disrupting mitochondrial function
Christopher M Jackson, Ayush Pant, Wikum Dinalankara, et al.
The New England Journal of Medicine
|
June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
BMC Systems Biology
|
November 7, 2015
A multi-omic analysis of human naïve CD4+ T cells
Christopher J Mitchell, Derese Getnet, Min-Sik Kim, et al.
Journal for Immunotherapy of Cancer
|
April 18, 2020
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
Paolo Antonio Ascierto, Bernard A Fox, Walter J Urba, et al.
Cancer Discovery
|
December 9, 2024
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Lisa N Chesner, Fanny Polesso, Julie N Graff, et al.
Nature Medicine
|
August 15, 2022
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Christine D Palmer, Amy R Rappaport, Matthew J Davis, et al.
The Lancet. Oncology
|
June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
Mohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
European Urology
|
January 30, 2023
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study
Noah M Hahn, Michael A O'Donnell, Jason A Efstathiou, et al.
Page
of 27